Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia

Br J Haematol. 2020 Aug;190(3):e128-e130. doi: 10.1111/bjh.16901. Epub 2020 Jun 26.

Authors

Amita Ranger¹, Ruby Haji¹, Richard Kaczmarski², Akila Danga¹

Affiliations

¹ Hillingdon Hospitals NHS Foundation Trust, Uxbridge, UK.
² Department of Haematology, Hillingdon Hospitals, Hillingdon, UK.

No abstract available

Keywords: chronic myeloid leukaemia; coronavirus; tocilizumab.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Betacoronavirus*
COVID-19
Coronavirus Infections / complications*
Coronavirus Infections / diagnostic imaging
Coronavirus Infections / immunology
Coronavirus Infections / therapy
Cytokine Release Syndrome / drug therapy*
Cytokine Release Syndrome / immunology
Cytokine Release Syndrome / virology
Humans
Immunosuppressive Agents / therapeutic use*
Interleukin-6 / antagonists & inhibitors*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
Male
Middle Aged
Pandemics
Pneumonia, Viral / complications*
Pneumonia, Viral / diagnostic imaging
Pneumonia, Viral / immunology
Pneumonia, Viral / therapy
SARS-CoV-2
Tomography, X-Ray Computed

Substances

Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
Interleukin-6
tocilizumab